Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo Steps Up Development of New Diabetes Drug (Japan)

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo Co. is accelerating development of a candidate compound to treat type 2 diabetes. CS-011 is a glitazone-type drug that promotes absorption of sugars from the blood by activating muscle and fat tissues, and also inhibits the release of sugars from the liver. Both Takeda Pharmaceutical Co. and GlaxoSmithKline Plc are already marketing glitazone diabetes drugs, and each is enjoying sales of roughly 300 billion yen a year. According to Daiichi Sankyo, its candidate compound CS-011 has a different molecular structure than these two drugs and promises to be more effective. The company has now moved into the third and final phase of clinical trials on CS-011 in Europe and the U.S., and has also moved into phase II efficacy trials in Japan. It hopes to develop this diabetes compound into a mainline product that can stand shoulder to shoulder with its hyperlipidemia drug. (Print Edition Only: Link To Full Text Unavailable

You may also be interested in...

Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs

Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.

Veklury Takes Gilead Earnings On Wild Ride

The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.

Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations

The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts